.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
US Army
UBS
Farmers Insurance
Healthtrust
QuintilesIMS
Colorcon
Teva
Merck
Medtronic

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,242,131

« Back to Dashboard

Which drugs does patent 8,242,131 protect, and when does it expire?


Patent 8,242,131 protects INTERMEZZO and is included in one NDA. There has been one Paragraph IV challenge on Intermezzo.

This patent has sixteen patent family members in thirteen countries.

Summary for Patent: 8,242,131

Title:Methods of treating middle-of-the-night insomnia
Abstract: The present invention provides compositions and methods for treating middle-of-the-night insomnia without residual sedative effects upon awakening by administering low doses (about 5 mg or less) of zolpidem or a salt thereof.
Inventor(s): Singh; Nikhilesh (Mill Valley, CA), Pather; Sathasivan Indiran (Greenbrae, CA)
Assignee: Transcept Pharmaceuticals, Inc. (Pt. Richmond, CA)
Application Number:11/439,874
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Purdue PharmaINTERMEZZOzolpidem tartrateTABLET;SUBLINGUAL022328-001Nov 23, 2011ABRXYesNo► Subscribe► SubscribeMETHOD OF TREATING MIDDLE-OF-THE-NIGHT INSOMNIA► Subscribe
Purdue PharmaINTERMEZZOzolpidem tartrateTABLET;SUBLINGUAL022328-002Nov 23, 2011ABRXYesYes► Subscribe► SubscribeMETHOD OF TREATING MIDDLE-OF-THE-NIGHT INSOMNIA► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,242,131

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,252,809Compositions for treating insomnia► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,242,131

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
World Intellectual Property Organization (WIPO)2006128022► Subscribe
New Zealand563979► Subscribe
Mexico2007014679► Subscribe
South Korea20130042041► Subscribe
South Korea20080031208► Subscribe
Japan2013040175► Subscribe
Japan2008542299► Subscribe
Israel229039► Subscribe
Israel187309► Subscribe
Hong Kong1118203► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Daiichi Sankyo
Fuji
Teva
Queensland Health
Cantor Fitzgerald
Fish and Richardson
Moodys
US Department of Justice
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot